These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36225091)

  • 1. Effects of Hemodilution on Clot Waveform Analysis Parameters, Clotting Factors, and Thrombin Generation Assays in a Dilutional Model Based on Analysis of 11 Healthy Male Blood Donors.
    Ichikawa J; Okazaki R; Fukuda T; Yoon D; Komori M
    Med Sci Monit; 2022 Oct; 28():e937368. PubMed ID: 36225091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin.
    Cheong MA; Tan CW; Wong WH; Kong MC; See E; Yeang SH; Koh SK; Shim YT; Lee LH; Ng HJ
    Hematology; 2022 Dec; 27(1):337-342. PubMed ID: 35255239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.
    Darlington DN; Delgado AV; Kheirabadi BS; Fedyk CG; Scherer MR; Pusateri AE; Wade CE; Cap AP; Holcomb JB; Dubick MA
    J Trauma; 2011 Nov; 71(5):1152-63. PubMed ID: 21610535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expressiveness of global coagulation parameters in dilutional coagulopathy.
    Weiss G; Lison S; Spannagl M; Heindl B
    Br J Anaesth; 2010 Oct; 105(4):429-36. PubMed ID: 20693180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
    Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
    Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
    J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.
    Kato K; Hatayama Y; Shimohiro H; Ichikawa H; Fukuda T
    Yonago Acta Med; 2022 Aug; 65(3):226-230. PubMed ID: 36061578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
    Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
    J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry.
    Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE
    Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-19.
    Ichikawa J; Okazaki R; Fukuda T; Ono T; Ishikawa M; Komori M
    J Thromb Thrombolysis; 2022 Jan; 53(1):118-122. PubMed ID: 34263423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
    Tan CW; Cheen MHH; Wong WH; Wu IQ; Chua BLW; Ahamedulla SH; Lee LH; Ng HJ
    Biochem Med (Zagreb); 2019 Jun; 29(2):020710. PubMed ID: 31223264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose fibrinogen versus a clinically recommended dose of fresh frozen plasma for reversal of dilutional coagulopathy in an in vitro model of severe hemodilution.
    Rosenthal C; Rau J; Volk T; Sander M; Ziemer S; Von Heymann C
    Minerva Anestesiol; 2014 Aug; 80(8):894-903. PubMed ID: 24398441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
    Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation Status Using Clot Wave Analysis in Patients With Prolonged Immobilization.
    Iberahim S; Muhamat Yusoff R; Mohd Noor NH; Hassan R; Ramli NN; Bahar R; Zulkafli Z; Wan Ab Rahman WS; Ab Ghani AS
    Cureus; 2024 Jan; 16(1):e51483. PubMed ID: 38304638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clot waveform analysis with or without adjustment between prothrombin time and activated partial thromboplastin time assays to assess in vitro effects of direct oral anticoagulants.
    Wakui M; Fujimori Y; Ozaki Y; Oka S; Ziparo M; Osada E; Kondo Y; Nakagawa T; Nakamura S; Matsushita H
    Clin Chim Acta; 2024 Aug; 562():119887. PubMed ID: 39059480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global coagulation assays in hemophilia A: A comparison to conventional assays.
    Aghighi S; Riddell A; Lee CA; Brown SA; Tuddenham E; Chowdary P
    Res Pract Thromb Haemost; 2020 Feb; 4(2):298-308. PubMed ID: 32110761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.